<p>Eledon Pharmaceuticals, Inc.（納斯達克代碼：ELDN - 獲取免費報告）週一的股價下跌了 3.4%。該公司的股價最低曾達到$3.96，最後交易價為$4.01。在午盤交易中，約有 395,521 股成交，較平均每日成交量 265,548 股增加了 49%。該股票此前收盤價為$4.15。</p>
<p>獲取 <strong>Eledon Pharmaceuticals</strong> 的提醒：</p>
<h2>分析師設定新目標價</h2>
<p>ELDN 已成為多份研究報告的主題。HC Wainwright 在 11 月 20 日的報告中重申了對 Eledon Pharmaceuticals 的 “買入” 評級，並設定了$16.00 的目標價。Guggenheim 在 1 月 28 日的報告中開始覆蓋 Eledon Pharmaceuticals 的股票。他們為該公司設定了 “買入” 評級和$9.00 的目標價。</p>
<p><strong>查看我們關於 ELDN 的最新研究報告</strong></p>
<h2>Eledon Pharmaceuticals 的價格表現</h2>
<p>該公司的市值為 2.3955 億美元，市盈率為-2.00，貝塔值為 0.79。該公司的 50 日移動平均價格為$4.35，200 日移動平均價格為$3.79。</p>
<h2>對 Eledon Pharmaceuticals 的對沖基金看法</h2>
<p>幾家對沖基金和其他機構投資者最近修改了對該公司的持股。RA Capital Management L.P.在第四季度收購了 Eledon Pharmaceuticals 的新股份，價值約為$14,693,000。First Light Asset Management LLC 在第四季度收購了 Eledon Pharmaceuticals 的新股份，價值約為$9,595,000。Blue Owl Capital Holdings LP 在第四季度收購了 Eledon Pharmaceuticals 的新股份，價值約為$8,075,000。Sphera Funds Management LTD.在第四季度將其在 Eledon Pharmaceuticals 的持股增加了 96.7%。Sphera Funds Management LTD.現在擁有該公司 2,551,619 股股票，價值$10,513,000，在此期間又購買了 1,254,298 股。最後，Frazier Life Sciences Management L.P.在第四季度收購了 Eledon Pharmaceuticals 的新股份，價值約為$4,848,000。機構投資者和對沖基金持有該公司 56.77% 的股票。</p>
<h2>關於 Eledon Pharmaceuticals</h2>
<p>（獲取免費報告）</p>
<p>Eledon Pharmaceuticals, Inc 是一家臨牀階段的生物技術公司。該公司利用其免疫學專業知識，針對 CD40 配體（CD40L，也稱為 CD154）通路開發療法，以保護移植器官並防止排斥，以及治療肌萎縮側索硬化症（ALS）。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Eledon Pharmaceuticals</li>
<li>市值計算器：如何計算市值</li>
<li>看跌投資者可以在抗衰退 ETF 中尋求避難所</li>
<li>如何計算退休收入：MarketBeat 的計算器</li>
<li>3 只超賣的七隻奇蹟股票在關鍵水平：現在買入？</li>
<li>航空公司股票 - 現在值得購買的頂級航空公司股票</li>
<li>3M 將在年中達到$175，並且更高的高點是可能的</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Eledon Pharmaceuticals 嗎？</h2>
<p>在考慮 Eledon Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Eledon Pharmaceuticals 並不在名單上。</p>
<p>雖然 Eledon Pharmaceuticals 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

ELDN

<p>Eledon Pharmaceuticals（納斯達克代碼：ELDN）股價在交易中下跌 3.4%，至 4.01 美元，成交量較平均水平增加 49%。分析師們設定了價格目標，HC Wainwright 維持 “買入” 評級，目標價為 16.00 美元，而 Guggenheim 則設定了 9.00 美元的目標。機構投資者持有該股票的 56.77%。Eledon 專注於免疫學，開發器官移植保護和 ALS 治療的療法</p>

<p>Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report)'s share price dropped 3.4% during trading on Monday . The company traded as low as $3.96 and last traded at $4.01. Approximately 395,521 shares traded hands during mid-day trading, an increase of 49% from the average daily volume of 265,548 shares. The stock had previously closed at $4.15.</p>
<div class="lb-trans"><p>Eledon Pharmaceuticals, Inc.（納斯達克代碼：ELDN - 獲取免費報告）週一的股價下跌了 3.4%。該公司的股價最低曾達到$3.96，最後交易價為$4.01。在午盤交易中，約有 395,521 股成交，較平均每日成交量 265,548 股增加了 49%。該股票此前收盤價為$4.15。</p>
</div><p>Get <strong>Eledon Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Eledon Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>ELDN has been the subject of a number of research reports. HC Wainwright reaffirmed a &#34;buy&#34; rating and issued a $16.00 price objective on shares of Eledon Pharmaceuticals in a report on Wednesday, November 20th. Guggenheim started coverage on shares of Eledon Pharmaceuticals in a report on Tuesday, January 28th. They set a &#34;buy&#34; rating and a $9.00 price target for the company.</p>
<div class="lb-trans"><p>ELDN 已成為多份研究報告的主題。HC Wainwright 在 11 月 20 日的報告中重申了對 Eledon Pharmaceuticals 的 “買入” 評級，並設定了$16.00 的目標價。Guggenheim 在 1 月 28 日的報告中開始覆蓋 Eledon Pharmaceuticals 的股票。他們為該公司設定了 “買入” 評級和$9.00 的目標價。</p>
</div><p><strong>Check Out Our Latest Research Report on ELDN</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 ELDN 的最新研究報告</strong></p>
</div><h2>Eledon Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Eledon Pharmaceuticals 的價格表現</h2>
</div><p>The company has a market cap of $239.55 million, a price-to-earnings ratio of -2.00 and a beta of 0.79. The firm's fifty day moving average price is $4.35 and its 200-day moving average price is $3.79.</p>
<div class="lb-trans"><p>該公司的市值為 2.3955 億美元，市盈率為-2.00，貝塔值為 0.79。該公司的 50 日移動平均價格為$4.35，200 日移動平均價格為$3.79。</p>
</div><h2>Hedge Funds Weigh In On Eledon Pharmaceuticals</h2>
<div class="lb-trans"><h2>對 Eledon Pharmaceuticals 的對沖基金看法</h2>
</div><p>Several hedge funds and other institutional investors have recently modified their holdings of the company. RA Capital Management L.P. acquired a new stake in Eledon Pharmaceuticals in the fourth quarter worth about $14,693,000. First Light Asset Management LLC acquired a new stake in Eledon Pharmaceuticals in the fourth quarter worth about $9,595,000. Blue Owl Capital Holdings LP acquired a new stake in Eledon Pharmaceuticals in the fourth quarter worth about $8,075,000. Sphera Funds Management LTD. lifted its holdings in Eledon Pharmaceuticals by 96.7% in the fourth quarter. Sphera Funds Management LTD. now owns 2,551,619 shares of the company's stock worth $10,513,000 after purchasing an additional 1,254,298 shares during the period. Finally, Frazier Life Sciences Management L.P. acquired a new stake in Eledon Pharmaceuticals in the fourth quarter worth about $4,848,000. Institutional investors and hedge funds own 56.77% of the company's stock.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近修改了對該公司的持股。RA Capital Management L.P.在第四季度收購了 Eledon Pharmaceuticals 的新股份，價值約為$14,693,000。First Light Asset Management LLC 在第四季度收購了 Eledon Pharmaceuticals 的新股份，價值約為$9,595,000。Blue Owl Capital Holdings LP 在第四季度收購了 Eledon Pharmaceuticals 的新股份，價值約為$8,075,000。Sphera Funds Management LTD.在第四季度將其在 Eledon Pharmaceuticals 的持股增加了 96.7%。Sphera Funds Management LTD.現在擁有該公司 2,551,619 股股票，價值$10,513,000，在此期間又購買了 1,254,298 股。最後，Frazier Life Sciences Management L.P.在第四季度收購了 Eledon Pharmaceuticals 的新股份，價值約為$4,848,000。機構投資者和對沖基金持有該公司 56.77% 的股票。</p>
</div><h2>About Eledon Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Eledon Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).</p>
<div class="lb-trans"><p>Eledon Pharmaceuticals, Inc 是一家臨牀階段的生物技術公司。該公司利用其免疫學專業知識，針對 CD40 配體（CD40L，也稱為 CD154）通路開發療法，以保護移植器官並防止排斥，以及治療肌萎縮側索硬化症（ALS）。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Eledon Pharmaceuticals</li>
<li>Market Cap Calculator: How to Calculate Market Cap</li>
<li>Bearish Investors Can Seek Refuge in Recession-Resistant ETFs</li>
<li>How to Calculate Retirement Income: MarketBeat’s Calculator</li>
<li>3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?</li>
<li>Airline Stocks - Top Airline Stocks to Buy Now</li>
<li>3M to Hit $175 by Mid-Year, and Higher Highs Are Likely</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Eledon Pharmaceuticals</li>
<li>市值計算器：如何計算市值</li>
<li>看跌投資者可以在抗衰退 ETF 中尋求避難所</li>
<li>如何計算退休收入：MarketBeat 的計算器</li>
<li>3 只超賣的七隻奇蹟股票在關鍵水平：現在買入？</li>
<li>航空公司股票 - 現在值得購買的頂級航空公司股票</li>
<li>3M 將在年中達到$175，並且更高的高點是可能的</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eledon Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Eledon Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Eledon Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Eledon Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eledon Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Eledon Pharmaceuticals 並不在名單上。</p>
</div><p>While Eledon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Eledon Pharmaceuticals 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Eledon Pharmaceuticals（納斯達克股票代碼：ELDN）股價下跌 3.4% - 以下是原因